The high mortality of ovarian cancer is caused by the dissemination of cancer cells within the abdominal cavity. While adhesion of tumor cells to the peritoneum is mediated through integrins, migration and invasion is mediated at least in part by the expression of the protease urokinase (uPA) and its receptor (u-PAR). Our preliminary studies show that beta 3-integrin expression represses uPA and u-PAR transcription. This lead to our general HYPOTHESIS that adhesion receptors can regulate the uPA/u-PAR proteolytic system and thereby modulate invasion.
SPECIFIC AIMS : We will study the effect of beta 3-integrin expression and inhibition on uPA/u-PAR regulation in ovarian cancer cells. A 3D model of peritoneum will be assembled, using primary human peritoneal fibroblasts and mesothelial cells, for the purpose of evaluatingthe contributionof stromal cells to beta 3-integrin mediated invasion and adhesion. We will use a mouse model to assess adhesion, dissemination, and growth of beta3 integrin expressing ovarian cancer cells adherent to the peritoneum and floating in ascites (Aim 1). Our hypothesis is that by understanding the signaling events by which integrins regulate u-PAR/urokinase expression we will be able to improve our understanding of protease transcription. Since our preliminary data show that NF-KB is involved in protease regulation, we will determine (Aim 2) whether the NF-KB pathway regulates the adhesion, invasion and expression of u-PAR and uPA in vivo, and also ascertain how beta3 integrin regulates u-PAR and uPA promoter activity. Our preliminary studies implicate a footprinted region (-238/-260), bound with the transcription factor PEA3, that mediates inhibition of u-PAR by the beta 3-integrin. To uncover the transcriptionalmechanism by which PEA3 regulates u-PAR we will (Aim 3) determine if beta3-integrin affects PEA3 synthesis or involves the trans-acting activityof PEA3 and identify those residues in PEA3 which are altered by phosphorylation, thereby affecting promoter activity. Finally, we will validate the mechanism we have elucidated with ovarian cancer cell lines, in vivo, by measuring the binding of PEA3 (EMSA, ChIP) to the uPA/u-PAR promoter in human ovarian cancer tissue of various stages and differentiation, and comparing it to normal ovary. SIGNIFICANCE: The long-term goal of our studies is the understanding of adhesion and invasion in ovarian cancer in order to design a rationale approach enabling us to interfere with molecular mechanisms that regulate metastasis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA111882-05
Application #
7772329
Study Section
Tumor Progression and Metastasis Study Section (TPM)
Program Officer
Sathyamoorthy, Neeraja
Project Start
2006-04-01
Project End
2012-02-28
Budget Start
2010-03-01
Budget End
2012-02-28
Support Year
5
Fiscal Year
2010
Total Cost
$264,562
Indirect Cost
Name
University of Chicago
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Li, Gang; Montgomery, Jeffrey E; Eckert, Mark A et al. (2017) An activity-dependent proximity ligation platform for spatially resolved quantification of active enzymes in single cells. Nat Commun 8:1775
Sundaram, Karthik M; Zhang, Yilin; Mitra, Anirban K et al. (2017) Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity. Cancer Res 77:1684-1696
Chiyoda, Tatsuyuki; Hart, Peter C; Eckert, Mark A et al. (2017) Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. Cancer Prev Res (Phila) 10:255-266
Zhang, Yilin; Sriraman, Shravan Kumar; Kenny, Hilary A et al. (2016) Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform. Mol Cancer Ther 15:2282-2293
Coscia, F; Watters, K M; Curtis, M et al. (2016) Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nat Commun 7:12645
Eckert, Mark A; Pan, Shawn; Hernandez, Kyle M et al. (2016) Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov 6:1342-1351
Lengyel, Ernst; Litchfield, Lacey M; Mitra, Anirban K et al. (2015) Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol 212:479.e1-479.e10
Kenny, Hilary A; Lal-Nag, Madhu; White, Erin A et al. (2015) Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nat Commun 6:6220
Peters, Pamela N; Schryver, Elizabeth M; Lengyel, Ernst et al. (2015) Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity. J Vis Exp :e53541
Litchfield, Lacey M; Mukherjee, Abir; Eckert, Mark A et al. (2015) Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. Oncotarget 6:23548-60

Showing the most recent 10 out of 50 publications